Update shared on 31 Oct 2025
Fair value Increased 11%Axogen’s analyst price target has increased from $24.71 to $27.38. Analysts cite robust third-quarter performance and a heightened growth outlook for 2025 as the key drivers behind their upward revisions.
Analyst Commentary
Recent Street Research highlights a positive shift in analyst sentiment following Axogen's strong quarterly results and improved growth outlook. Their analyses focus on both upward drivers and points for consideration regarding future performance.
Bullish Takeaways
- Bullish analysts are encouraged by Axogen's robust third-quarter performance, with sales exceeding consensus expectations by approximately 6%.
- The company has raised its guidance for 2025, now anticipating at least 19% year-over-year sales growth, which supports a heightened growth trajectory.
- Upward price target revisions reflect renewed confidence in Axogen’s ability to deliver continued revenue growth through effective execution of its market development strategy.
- Consistent "Buy" ratings from research firms emphasize strong execution across major operational areas. This illustrates belief in the company's strategic direction and value proposition.
What's in the News
- Axogen, Inc. raised its 2025 earnings guidance twice this year and is currently projecting at least 19% revenue growth, or $222.8 million, with an anticipated gross margin of 73% to 75% (Key Developments).
- The U.S. Food and Drug Administration extended the review period for Axogen's Biologics License Application for Avance Nerve Graft by three months. The new goal date for a decision is December 5, 2025. The extension allows the agency additional time to review substantial new manufacturing and facility data (Key Developments).
- The FDA is expected to provide feedback on Axogen's product labeling in November 2025 as part of the PDUFA review procedures (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has risen from $24.71 to $27.38, reflecting increased optimism about Axogen's outlook.
- Discount Rate has decreased slightly from 7.68% to 7.59%, suggesting a modestly lower perceived risk in future cash flows.
- Revenue Growth expectations declined from 16.70% to 15.92%, indicating a more conservative forward sales projection.
- Net Profit Margin is projected to increase significantly from 7.96% to 19.44%. This signals improved operating efficiency and profitability expectations.
- Future P/E ratio estimate has dropped substantially from 62.40x to 27.79x. This points to lower anticipated earnings multiples due to stronger profit forecasts.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.